Publication in Nature Reviews Drug Discovery

Engaging sufficient numbers of patients with cancers that have particular molecular characteristics is a key challenge in building evidence to support precision cancer medicine. This is addressed in an article by Kjetil Taskén (OUS) and Piers Mahon (DIGICORE, Fondation Universitaire, Brussels) recently published in Nature Reviews Drug Discovery.

The authors discuss how oncology real-world evidence (RWE) networks such as the DIGIONE (Digital Oncology Network for Europe) and a network of pragmatic trials such as the DRUP-like clinical trials in PRIME-ROSE can contribute to accelerate indication expansion for existing cancer therapies. Thus, integrating these approaches can help bringing treatments to new patient populations faster and more efficiently.

‍

You can download the full paper below.

‍

Accelerating precision oncology by converging pragmatic trials and real-world evidence

Taskén K, Mahon P

Nature Reviews Drug Discovery

doi: https://doi.org/10.1038/d41573-025-00047-5

‍